Imaging mass spectrometry demonstrates age-related decline in human adipose plasticity

Christelle Guillermier,1,2,3 Pouneh K. Fazeli,3,4 Soomin Kim,1 Mingyue Lun,1 Jonah P. Zuflacht,5 Jessica Milian,6 Hang Lee,3,6 Hugues Francois-Saint-Cyr,7 Francois Horreard,8 David Larson,7 Evan D. Rosen,3,9,10 Richard T. Lee,3,4,10,11,12 Claude P. Lechene,1,2,3 and Matthew L. Steinhauser1,2,3,10,11

1Department of Medicine, Division of Genetics, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 2Center for NanoImaging, Brigham and Women’s Hospital, Cambridge, Massachusetts, USA. 3Harvard Medical School, Boston, Massachusetts, USA. 4Department of Medicine, Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 5Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 6Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA. 7CAMECA, Madison, Wisconsin, USA. 8CAMECA, Gennevilliers, France. 9Department of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 10Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. 11Harvard Stem Cell Institute and 12Department of Stem Cell and Regenerative Medicine, Harvard University, Cambridge, Massachusetts, USA.

Introduction

Rates of homeostatic cell turnover and cellular responses to tissue stress or injury have been actively debated for a range of organs. One such example is adipose tissue, for which estimated rates of homeostatic adipocyte turnover differ by over one order of magnitude (1–7). Landmark studies leveraging the global carbon-14 pulse that ensued in the 20th century after above-ground nuclear testing applied carbon-14 birth dating and population modeling to retrospectively infer the dynamics of human neurogenesis (8), cardiogenesis (9), adipogenesis (1), and adipocyte lipid turnover (10). The carbon-14 birth-dating methodology, however, cannot easily be applied to prospective human studies, because carbon-14 exposure is not a controllable variable and because cell birth or synthesis of new biomolecules is not directly measured.

This provided rationale for translation of multi-isotope imaging mass spectrometry (MIMS) — an imaging method that enables multiplexed measurement of stable isotope tracers with subcellular resolution (11, 12). The translation of MIMS to humans builds on extensive precedent for the safe utilization of stable isotopes in metabolic studies (13), including in vulnerable populations, such as pregnant women and critically ill infants (14). MIMS is made possible by an ion microscope (NanoSIMS) (15), which incorporates principles of secondary ion mass spectrometry (16, 17) and state-of-the-art ion optics. A sample surface is sputtered with a focused primary ion beam, triggering emission of atoms and molecular fragments, a fraction of which are ionized and transmitted to a mass spectrometer. Through improved spatial resolution (<50 nm) and mass resolution, more efficient secondary ion transmission, and the capability to accurately measure multiple ionic species in parallel, the NanoSIMS instrument facilitates the fundamental goal of
MIMS: to quantitatively localize stable isotope tracers in subcellular domains within a reasonable amount of time (11). Here, we present a first-in-human MIMS study, in which leukocytosis is utilized as a model to develop the methodology, which in turn is applied to a proof-of-concept study of adipogenesis and adipocyte lipid turnover in subcutaneous adipose tissue (SAT).

Results

Measurement of human cell birth with stable isotope tracers and MIMS. To establish a method for quantification of cell birth in humans, we adapted labeling protocols first developed for the measurement of cell division and fate in mice (12). We administered \(^{15}\text{N}\)-thymidine intravenously to 6 healthy adult volunteers for 48 hours (Table 1). Peripheral blood and SAT biopsies were collected after pulse and again after a 4-week chase, and the peripheral white blood cell fraction was utilized to validate the labeling protocol. Monocyte, granulocyte, and lymphocyte subpopulations were identified by their stereotypical appearance (Figure 1A). Labeled monocytes were evident in the peripheral blood at the conclusion of the 48-hour pulse (Figure 1B), consistent with monocyte dynamics in mice (18). In contrast, labeled lymphocytes were evident in circulation after a 1-month chase, consistent with a longer period of differentiation in the marrow before their release into the circulation. In the absence of more frequent sampling during label pulse and chase, these data cannot provide a complete picture of the dynamics of leukocyte birth and trafficking. These data do, however, establish the feasibility and reproducibility of detecting cell birth with MIMS after pulse-chase administration of stable isotope-tagged thymidine (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.90349DS1).

Practical considerations limit long-term intravenous administration of thymidine to detect rare birth events, which provided the rationale for the development of a second method, building on the precedent of long-term oral \(^2\text{H}\)-water administration as a tracer for DNA synthesis in bulk tissue samples (3). Although water is a nonspecific substrate for biosynthetic reactions, we reasoned that the rapid replication of cellular constituents, including DNA, during cell division would result in higher label incorporation relative to background incorporation due to homeostatic turnover of molecules in nondividing cells. Moreover, signal in highly stable constituents, such as DNA, should become more distinct during label-free chase with dilution of nonspecific background labeling. To establish the utility of \(^2\text{H}\)-water labeling, we recruited 3 healthy volunteers, to whom oral \(^2\text{H}\)-water was administered concurrently with intravenous \(^{15}\text{N}\)-thymidine (Figure 1C). Similar to the 2-day protocol, \(^{15}\text{N}\)-labeled cells at completion of pulse were primarily monocytes, whereas those labeled at the end of chase were primarily lymphocytes (Figure 1D). In both cell types, \(^{15}\text{N}\) cells were highly \(^2\text{H}\) labeled (Figure 1, D–G). In the lymphocyte population after chase, however, some \(^2\text{H}\)-labeled cells were \(^{15}\text{N}\) unlabeled, an observation that we attribute to the longer half-life of water in humans (19), relative to thymidine, resulting in prolongation of the effective labeling period with \(^2\text{H}\)-water relative to that achieved with a similar duration of \(^{15}\text{N}\)-thymidine administration. These data therefore support the utilization of either \(^{15}\text{N}\)-thymidine or \(^2\text{H}\)-water to track cell division, in vivo, in humans with MIMS.

MIMS demonstrates birth of new adipocytes in SAT. To assess adipocyte birth, we analyzed SAT specimens collected from subjects administered intravenous \(^{15}\text{N}\)-thymidine for either 2 or 3 days (protocols 1 and 2), followed by a 1-month label-free chase. Through an approach previously applied to murine adipose tissue (6), we identified adipocyte nuclei by their close association to a defining lipid droplet. We analyzed adipocyte samples collected after a 1-month chase to account for the requisite time for progenitor differentiation.

Table 1. Baseline characteristics of study participants

<table>
<thead>
<tr>
<th>Protocol 1 ((^{15}\text{N}) thymidine × 48 h) n = 6</th>
<th>Protocol 2 ((^{15}\text{N}) thymidine × 72 h + (^2\text{H}_2\text{O}) n = 3</th>
<th>Protocol 3 ((^2\text{H}_2\text{O} \times 1) mo) n = 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>40.3 ± 3.1 (range: 31–48)</td>
<td>33.3 ± 6.1 (range: 23–44)</td>
</tr>
<tr>
<td>Male/female</td>
<td>3/3</td>
<td>3/0</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>172.8 ± 3.8</td>
<td>174.7 ± 4.1</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>76.9 ± 3.5</td>
<td>77.3 ± 3.9</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>25.7 ± 0.6 (23.5–27.3)</td>
<td>25.4 ± 0.8 (24.4–27)</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>87.8 ± 7.2</td>
<td>83 ± 11.9</td>
</tr>
</tbody>
</table>

\(^a\)Median [interquartile range].
which occurs within approximately 2 weeks, based on labeling studies in mouse models. We detected five
15N-thymidine–labeled cells (Figure 2A, n = 5,033 total nuclei, n = 657 adipocyte nuclei); however, all of
the labeled cells were nonadipocyte stromal-vascular cells. A calculation of the probability of obtaining this
result for different hypothetical yearly adipocyte birth rates (Figure 2B) suggests that the true birth rate is
less than approximately 75% per year (95% certainty).

In addition to the low rate of homeostatic adipocyte turnover, capturing rare labeling events in adipose
tissue is further challenged by the large size of adipocytes relative to their nuclei, which results in a low fre-
quency of adipocyte nuclei in any given imaging plane and large swaths of effective analytical dead space.
We reasoned that an alternative approach to detecting rare adipocyte birth would be to increase the effec-
tive labeling frequency by extending the labeling duration. Therefore, we administered 2H-labeled water
orally to 9 healthy adults for 4 weeks. The primary analytical endpoint was measurement of 2H-labeling
in adipocyte nuclei after a 6-month label-free chase. At this time point, a small subset of adipocyte nuclei
demonstrated markedly elevated 2H-labeling in a pattern similar to the chromatin, consistent with a mean
frequency of 1.6% newly generated adipocytes (range = 0.7%–5.6%, Figure 3A).

The surge in lipid storage that occurs when progenitors differentiate into adipocytes provided a sec-
ond avenue to identify new adipocytes because H atoms from water are introduced by several pathways
of intermediate metabolism into glycerol and fatty acids, thereby resulting in the labeling of lipid with de
novo lipogenesis (Figure 3B) (7, 20, 21). Indeed, at the conclusion of pulse labeling, we identified a sub-
population of adipocytes containing lipid 2H-label that was 3–7 SDs from the mean. We reasoned that
such a population could arise due to one of two scenarios: either from de novo adipocyte differentiation
or due to an intrinsically higher rate of lipid turnover. Adipocytes with higher lipid turnover, however,
would also experience a more rapid rate of label decay during chase. Therefore, to distinguish these
two possibilities, we analyzed the normalized distribution of adipocyte lipid droplets at the conclusion of
2H-water labeling and then again after 6 months of label-free chase. This analysis demonstrated a
persistent subset of highly labeled adipocyte droplets after prolonged chase, consistent with their differ-
etiation during 2H-water labeling (Figure 3C). Importantly, the frequency of putative new adipocytes
based on high 2H-labeling positively correlated with the frequency of 2H-labeled adipocyte nuclei (Figure
3D), suggesting that the two approaches independently captured the frequency of new adipocyte forma-
tion. To project these frequencies into a yearly birth rate, we assumed that the effective labeling period
conferred by 4 weeks of 2H-water administration would be extended by one half-life of total body water
(~1 week) (19). This translated into a yearly adipocyte birth rate of approximately 11% (nuclei: median
[interquartile range] = 11% [8, 60%]; lipid droplet: mean = 12% ± SD 8%).

The adipogenesis measurements described here are lower than rates derived from bulk measurement
of 2H-water–labeled adipocytes isolated from subcutaneous adipose depots (0.16%–0.29% per day or 58%–
106% per year) (7) and yet similar to the approximate 10% turnover derived from the 14C birth-dating model
(1). One potential pitfall relevant to both methods is the reliance on purification and pooling of adipo-
cytes from enzymatically digested adipose tissue. Indeed, the 2H-water–labeling study reported adipocyte
purification efficacy of approximately 95% (7), whereas the 14C birth-dating study described optimization
to ≥98% (1). Variable degrees of contamination by the more highly proliferative stromal-vascular frac-

Figure 1. Measurement of human cell birth with MIMS. (A) 15N-thymidine–labeled leukocytes, collected after a 2-day intravenous labeling period or
subsequent 4-week label-free chase. Quantitative mass images reveal subcellular details. High phosphate content in nucleic acid accounts for high
signal in nuclei of 31P images. 32S images demonstrate intense signal in the granules contained in granulocytes. 15N/14N hue saturation intensity image
shows label localized to the nuclei of cells born during label administration (arrows). The rainbow scale ranges from blue, set to natural ratio (0.37%,
expressed as 0% above natural ratio), to red, where the ratio is above the natural ratio (200% = 3 times natural ratio). Scale bar: 5 μm. (B) Frequency
of labeled leukocyte subsets after pulse or chase (n = 6 subjects). Data displayed as Tukey box-and-whisker plots. Mann-Whitney tests were used to assess
significance. Note, the y axis ranges from 0%–20%. (significance. Labeling schematic for protocol 2, in which subjects were administered intravenous 15N-thymidine
continuously for 3 days concurrently with oral 2H-water. The expected effective labeling period for 2H-water is prolonged relative to 15N-thymidine due to
a total body water half-life of ~1 week. (G) Data from representative subject undergoing double-labeling protocol (n = 3). After pulse (left),
15N-thymidine–labeled monocytes demonstrate high 2H-water labeling relative to 15N-unlabeled cells. After chase (right), high 2H-labeling in 15N-thymidine–labeled lymphocytes relative to that observed in 15N-unlabeled cells. Rare 15N outliers that are highly 2H-labeled likely represent cells born after cessation of
15N-thymidine labeling but within the effective 2H-water–labeling period shown schematically in C. Data displayed as Tukey box-and-whisker plots. Mann-Whitney tests were used to assess significance. E.g., background.
H-lipid label. Once label is taken up into the adipocyte lipid droplet due to de novo lipogenesis, the sub-

Figure 2. Limited turnover of human SAT. (A) MIMS analysis of SAT sections after 15N-thymidine pulse-chase revealed rare 15N-labeled stromal-vascular cells. Top row: 2 labeled cells (arrows) are found adjacent to a blood vessel. Bottom: unlabeled adipocyte nucleus (arrows). Scale bar: 5 μm. (B) The probability of observing no labeled adipocyte nuclei (n = 657 analyzed), given different yearly turnover rates (x axis). At a probability of 0.05, the yearly adipocyte turnover rate is 75%, suggesting that there is a 95% probability that the yearly adipocyte turnover rate is 75% or less.

tion may account for previously reported differences in adipocyte birth. In taking advantage of the lateral imaging resolution of the MIMS instrument to distinguish adipocytes from adjacent interstitial structures, we propose that the present study is much less prone to such error. Moreover, because MIMS images are derived from the destructive sputtering and analysis of the surface atomic layers of the sample, they are representative of a small fraction of the standard 0.5-μm-thick sections, and therefore the depth resolution greatly exceeds the lateral resolution. This renders MIMS imaging much less prone to artifacts from compression of superimposed 3D objects into a 2D image. There is undoubtedly a low frequency of adipocytes that is excluded when the imaging plane captures the adipocyte nucleus en face, without sampling the lipid droplet. Such sampling errors should affect all adipocytes, whether labeled or unlabeled, and therefore are unlikely to represent a major source of error in the measurements of adipocyte birth.

MIMS demonstrates an age-dependent decline in human adipocyte birth. Can this study also reveal insight into the mechanistic control of human adipogenesis? Given that aging is associated with declining organ function and regenerative capacity, we hypothesized that age might also be a critical factor in homeostatic adipogenesis. Indeed, regardless of whether we utilized measures based on nuclear or lipid droplet 2H-labeling, we observed an inverse association between age and adipocyte birth across the rather narrow age span of 23 to 38 years in this population, consistent with a decline in homeostatic adipogenesis with aging (Figure 3E; R = –0.72 to –0.80; P < 0.03). As gender may modulate adiposity, we considered whether the negative association between age and adipogenesis could be accounted for by gender. However, the aging effect remained significant, even after controlling for gender (P ≤ 0.04). Adipocyte development is at least partially under hormonal control, providing a rationale to investigate candidate hormonal regulators, selected based on prior evidence supporting a regulatory role in adipocyte development or body fat distribution (22–27). We measured serum levels of leptin, adiponectin, and insulin-like growth factor-1 (IGF-1), the latter of which is also known to decline with age (28). Although we were principally interested in plasma samples collected at the 6-month chase time point, the same time point at which adipogenesis was measured, we also report hormone levels in plasma samples collected from the study subjects at earlier time points (end of pulse and after 1-month chase). We found a significant positive association between IGF-1 (as measured at all 3 time points) and adipogenesis, as measured by nuclei at the 6-month chase time point (pulse [R = 0.83, P < 0.01], 1-month chase [R = 0.90, P < 0.001], and 6-month chase [R = 0.88, P < 0.01]), suggesting that IGF-1 may be a hormonal mediator of adipogenesis (Table 2). Similarly, there was a strong association between IGF-1 measured in the 6-month plasma samples and adipogenesis, as measured by lipid droplet 2H-labeling at 6 months (Figure 3F; R = 0.68, P = 0.04). When we controlled for IGF-1 in a multivariable linear regression model examining the relationship between age and adipogenesis, we found that the significant association between age and adipogenesis was weakened with low variance inflation factors, suggesting that the relationship between adipogenesis and age may in part be mediated by differences in IGF-1 levels (Table 3). In contrast, we did not find a strong association between adipogenesis and adiponectin or leptin. Together, these data suggest that the age-dependent decline in adipogenesis could potentially be partially determined by a similar age-dependent decline in IGF-1.

MIMS demonstrates an age-dependent decline in adipocyte lipid turnover. This study also offered the opportunity to interrogate the metabolic function of SAT through an analysis of the uptake and release of 2H-lipid label. Once label is taken up into the adipocyte lipid droplet due to de novo lipogenesis, the subsequent decay of that signal reflects lipid turnover. Indeed, an initial analysis of the labeling distribution...
of adipocyte data for all subjects at the end of a 1-month pulse and again after a 6-month chase demonstrated a downward shift in the labeling distribution, consistent with lipid turnover. The intersubject variability of lipid turnover in this relatively homogeneous cohort was remarkably broad (lipid half-life mean = 13.5 month ± SD 11.9 month; Figure 4). Although such variability is consistent with prior studies (7, 10), we observed a previously unappreciated association between subject age and lipid age, such that lipid turnover decreased with increasing age. This relationship held when controlling for gender ($\beta = 2.5; P = 0.02$) or BMI ($\beta = 2.1, P < 0.04$). Moreover, when we controlled for IGF-1 levels, we found that the relationship also remained significant, suggesting that the strong association between age and lipid turnover is at least partially independent of IGF-1, gender, or BMI. It may be that the current MIMS study revealed an aging effect that was not detected in the larger carbon-14 study, because the measurements were more direct. Alternatively, the differences may be attributable to differences in the study populations. Our study is smaller and therefore not powered to detect all determinants of adipogenesis or lipid turnover. In addition, the carbon-14 study merged cohorts with obesity and combined hyperlipidemia (10); whereas our smaller cohort included normal weight and slightly overweight individuals (BMI range 20–26). Given these caveats, a larger study specifically designed to test the aging hypothesis will be required to definitively determine the effect of age on the dynamics of adipocyte lipid turnover.

**Discussion**

This first-in-human MIMS study establishes rates of adipogenesis and lipid turnover in the SAT of healthy adults, elucidating an age-dependent decline in both rates within a population of individuals with a narrow age range. These two indices reflect the function of two different cell types contained in adipose tissue. The mature adipocyte is defined by its capacity for storage and regulated release of lipids, whereas generation of new adipocytes is dependent on the self-renewal and differentiation of adipocyte progenitors. A decline in both of these seemingly disparate cellular functions, however, may...
in theory converge to reduce the plasticity of the subcutaneous depot. Therefore, these data raise the question of whether projection of the aging trend beyond the relatively young upper age limit of this cohort would contribute to the well-described loss of SAT volume and metabolically deleterious ectopic fat redistribution that occurs with advanced age (29, 30).

This study also implicates IGF-1 as a candidate determinant of subcutaneous adipogenesis, a concept consistent with the long-standing recognition that IGF-1 drives adipogenesis, in vitro (23), and more recent evidence that IGF-1 promotes adipocyte hyperplasia in mice (22). Given that impaired adipogenesis is also associated with insulin resistance (6, 31, 32), we speculate that a decline in IGF-1–mediated adipogenesis is one factor linking advanced age to insulin resistance. How might such a mechanism be reconciled with the reduction in insulin resistance reported in the contexts of growth hormone deficiency or resistance, in which levels of downstream IGF-1 are also reduced (33–35)? In contrast to the apparent metabolic advantage seen with severe, genetically mediated growth hormone resistance, levels of IGF-1 that fall in the low end of the physiologic range are associated with a higher risk of diabetes in aging adults (36). Moreover,

![Figure 4. Age-dependent decline in lipid turnover in human subcutaneous adipocytes.](image)

Table 2. Univariate associations between MIMS measurements of adipogenesis and lipid turnover as well as subject characteristics and hormone levels from protocol 3

<table>
<thead>
<tr>
<th></th>
<th>Adipogenesis, as measured by 2H-labeling of lipid droplets (n = 9)</th>
<th>Adipogenesis, as measured by 2H-labeling of nuclei (n = 9)</th>
<th>Lipid turnover (lipid age, n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>R = −0.72; P &lt; 0.03</td>
<td>R = −0.80; P = 0.01</td>
<td>R = 0.76; P = 0.02</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td>R = −0.46; P = 0.21</td>
<td>R = −0.59; P &lt; 0.10</td>
<td>R = 0.48; P = 0.19</td>
</tr>
<tr>
<td><strong>IGF-1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse</td>
<td>R = 0.45; P = 0.22</td>
<td>R = 0.83; P = 0.01</td>
<td>R = −0.43; P = 0.25</td>
</tr>
<tr>
<td>1-month chase</td>
<td>R = 0.54; P = 0.13</td>
<td>R = 0.90; P &lt; 0.001</td>
<td>R = −0.28; P = 0.46</td>
</tr>
<tr>
<td>6-month chase</td>
<td><strong>R = 0.68; P = 0.04</strong></td>
<td>R = 0.88; P &lt; 0.01</td>
<td>R = −0.23; P = 0.55</td>
</tr>
<tr>
<td><strong>Leptin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse</td>
<td>R = 0.31; P = 0.41</td>
<td>R = 0.17; P = 0.67</td>
<td>R = −0.17; P = 0.66</td>
</tr>
<tr>
<td>1-month chase</td>
<td>R = −0.60; P = 0.09</td>
<td><strong>R = −0.72; P &lt; 0.03</strong></td>
<td>R = 0.61; P = 0.08</td>
</tr>
<tr>
<td>6-month chase</td>
<td>R = 0.41; P = 0.27</td>
<td>R = 0.03; P = 0.93</td>
<td>R = −0.60; P &lt; 0.09</td>
</tr>
<tr>
<td><strong>Adiponectin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse</td>
<td>R = 0.50; P = 0.17</td>
<td>R = 0.60; P &lt; 0.09</td>
<td>R = −0.41; P = 0.28</td>
</tr>
<tr>
<td>1-month chase</td>
<td>R = 0.55; P = 0.12</td>
<td>R = 0.57; P = 0.11</td>
<td>R = −0.43; P = 0.25</td>
</tr>
<tr>
<td>6-month chase</td>
<td>R = 0.54; P = 0.14</td>
<td>R = 0.52; P = 0.15</td>
<td>R = −0.35; P = 0.36</td>
</tr>
<tr>
<td><strong>Mean adipocyte size</strong></td>
<td>R = −0.36; P = 0.34</td>
<td>R = −0.37; P = 0.33</td>
<td>R = 0.40; P = 0.28</td>
</tr>
</tbody>
</table>

Significant associations are bolded.
IGF-1–associated genetic variants identified in GWAS studies are positively associated with insulin resistance (37). Therefore, we speculate that adipose tissue aging — and an associated impairment in adipogenesis — is a negative consequence of the age-dependent decline in IGF-1. This provides rationale for future investigations into whether the improvement in insulin sensitivity observed with IGF-1 therapy is at least partially mediated by stimulation of adipocyte progenitor differentiation (38, 39).

How does MIMS complement existing methods of studying human cell turnover and metabolism, such as the measurement of stable isotope tracers in bulk samples (3) or the 14C approach (8), whereby measurements of cell or molecular age are utilized to retrospectively infer turnover? We propose that MIMS presents a unique combination of capabilities, including (a) quantitative imaging at high magnification of individual cells in their natural microenvironment, (b) measurement of metabolic processes with a large array of commercially available or custom-synthesized stable isotope tracers, (c) multiplexed tracer measurements, and (d) perhaps most importantly, the possibility of performing prospective studies with control of the timing/duration of label exposure in order to allow assessment of interventions, ranging from environmental manipulations to novel therapies. The most important limitation of this methodology is perhaps that it requires tissue sampling, which, for most studies of internal tissues, will require recruitment of research subjects that are undergoing surgery on the organ of interest as part of their clinical care. Nonetheless, we propose this approach as a template of broad relevance to human studies of cell turnover, regeneration, and metabolic function in diverse tissues and cell types.

Methods

Human subjects

Eighteen subjects (Table 1) participated in one of three different stable isotope–labeling protocols described below. Healthy adult subjects were recruited through online advertisements. Inclusion criteria consisted of a BMI of between 20 and 27 kg/m², no significant chronic medical disorders, and no current medications. Subjects were excluded if they had a history of keloid formation, active use of antiplatelet or antithrombotic medications, regular exercise more than 20 minutes per day, alcohol use in excess of 2 servings per day, drug use within the prior 6 months, active smoking within the prior 6 months, and/or if they had inadequate abdominal wall fat to allow safe biopsy. There were no specific dietary requirements for study participation, and subjects were not given specific instructions regarding diet. SAT biopsies were retrieved from the periumbilical region through the side wall of the umbilicus utilizing a Temno 14-gauge biopsy system (CareFusion) as described previously (40).

Stable isotope tracer protocols

Endotoxin-free 15N-thymidine and sterile 2H-water were obtained from Cambridge Isotope Laboratories Inc. Three labeling protocols were developed as described in more detail in Supplemental Figure 1 and as described below:

Protocol 1. 15N-thymidine was resuspended in 0.9% NaCl solution, filtered, and delivered intravenously as a 30-mg bolus, followed by a continuous 15 mg/h infusion for 48 hours (n = 6 subjects). At the conclusion of the 48-hour labeling period, peripheral blood and fat biopsies were collected. After completion of a 4-week label-free chase period, peripheral blood and fat biopsies were again collected.

Protocol 2. 15N-thymidine was resuspended in 0.9% NaCl solution, filtered, and delivered intravenously as a 30-mg bolus, followed by a continuous 15 mg/h infusion for 72 hours (n = 3 subjects). At the time the infusion was initiated, subjects consumed 400 ml sterile 2H-water. Subsequently, they ingested 60 ml sterile 2H-water daily for the remainder of the 72-hour labeling period. Fat biopsies and peripheral blood

Table 3. Multivariable association between subject age and parameters of adipogenesis, controlling for IGF-1 levels in protocol 3

<table>
<thead>
<tr>
<th></th>
<th>IGF-1 (t = end pulse)</th>
<th>IGF-1 (t = 1-month chase)</th>
<th>IGF-1 (t = 6-month chase)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adipogenesis, as measured by lipid droplet (n = 9)</td>
<td>β = –1.0; P = 0.09; VIF = 1.37</td>
<td>β = –0.91; P = 0.10; VIF = 1.31</td>
<td>β = –0.75; P = 0.15; VIF = 1.46</td>
</tr>
<tr>
<td>Adipogenesis, as measured by nuclei (n = 9)</td>
<td>β = –1.2; P = 0.25; VIF = 1.37</td>
<td>β = –1.2; P = 0.33; VIF = 1.31</td>
<td>β = –0.43; P = 0.63; VIF = 1.46</td>
</tr>
<tr>
<td>Lipid turnover, as measured by lipid age (n = 9)</td>
<td>β = 2.27; P = 0.05</td>
<td>β = 2.51; P = 0.03</td>
<td>β = 2.83; P = 0.02</td>
</tr>
</tbody>
</table>

VIF, variance inflation factor.
were collected at the conclusion of the labeling period and then again after a 4-week label-free chase.

**Protocol 3.** Subjects presented to the Brigham and Women's Hospital Clinical Research Center where they ingested 80 ml sterile $^2$H-water every 2 hours for 3 doses, for a total of 240 ml ($n = 9$ subjects). Subjects then consumed 60 ml sterile $^2$H-water daily for 4 weeks. Fat biopsies were performed at the conclusion of the labeling period and then again after 1 and 6 months of label-free chase. In the 3 months preceding the study, subjects were weight stable within 2 kg, as determined from either the medical record or self-report.

Over the course of the 7-month protocol, weight stability was also maintained within 2 kg.

### MIMS

**Instrumental configuration.** MIMS was performed with modifications to previously described analytical methods, utilizing the prototype instrument and the NanoSIMS 50L (CAMECA) (6, 11, 12). The isotope ratio of $^{15}$N/$^{14}$N ($^{15}$N-thymidine labeling) was measured as previously described by quantifying the $^{12}$C$^{15}$N–/$^{12}$C$^{14}$N– ratio (12).

Analysis of $^2$H/$^1$H ($^2$H-water labeling) was derived by measuring $^{12}$C$^2$H at the end of $^2$H-water labeling and again after 6 months of label-free chase. Standard half-life equations were utilized to determine lipid half-life and the related parameter of average lipid age: lipid $t_{1/2}$. To calculate how the observation of no $^{15}$N-thymidine–labeled nuclei (Figure 2) affects the probability of different yearly adipogenesis rates, we assumed homogeneity of the subjects and pooled the data, assuming that each measurement of an adipocyte nucleus was independent. The probability is expressed as $P (R_{avg yearly birth rate} \mid no \ 15^N \ nucleus) = [1 - R \times (no. \ days \ labeling / 365)]^{total \ no. \ nucleus}$, where $P$ represents probability, $R$ represents the hypothetical yearly birth rate, and $no \ 15^N \ nucleus$ represents the observed absence of $^{15}$N-thymidine-labeled adipocyte nuclei.

Metrics of lipid turnover were determined using the lipid droplet–labeling distributions measured at the end of $^2$H-water labeling and again after 6 months of label-free chase. Standard half-life equations were utilized to determine lipid half-life and the related parameter of average lipid age: lipid $t_{1/2}$. This approach involved staining the sections with DAPI to identify all nuclei in the imaging plane. The second approach involved identification of candidate adipocyte nuclei using differential interference contrast microscopy ($\times 50$ objective). In this permissive approach to identification of adipocyte nuclei, the observer scanned the section and recorded regions of interest for all adipocyte nuclei. Images obtained with the NanoSIMS were analyzed in a customized plugin (OpenMIMS; https://github.com/BWHCNI/OpenMIMS) of ImageJ (NIH) and assigned an identity of adipocyte or stromal-vascular cell.

**Adipose tissue.** Adipose tissue specimens were fixed with 4% PFA, processed, and analyzed with modifications to previously described methods. For analyses of adipose lipid droplets, samples were subjected to additional fixation with 2% osmium tetroxide (9 hours) followed by an overnight incubation with 1% osmium tetroxide and 1.5% potassium ferrocyanide prior to embedding in EPON or LR white resin. In the early phase of the study, samples were analyzed in automated chain analysis mode, covering large swaths of the section. Due to the low frequency of adipocyte nuclei in any given imaging plane, we assessed different strategies to increase yield, primarily through offline identification of regions of interest containing candidate nuclei, which allowed for targeted analysis of these preselected regions of interest. The first approach involved staining the sections with DAPI to identify all nuclei in the imaging plane. The second approach involved identification of candidate adipocyte nuclei using differential interference contrast microscopy ($\times 50$ objective). In this permissive approach to identification of adipocyte nuclei, the observer scanned the section and recorded regions of interest for all adipocyte nuclei. Images obtained with the NanoSIMS were analyzed in a customized plugin (OpenMIMS; https://github.com/BWHCNI/OpenMIMS) of ImageJ (NIH) and assigned an identity of adipocyte or stromal-vascular cell.

**Hormonal analyses.** Total adiponectin was measured in plasma by ELISA (R&D Systems) with an intra-assay coefficient of variation (CV) of 2.5%–4.7% and an interassay CV of 5.8%–6.9%. Total leptin was measured in plasma by ELISA (R&D Systems) with an intra-assay CV of 3.0%–3.3% and an interassay CV of 5.8%–6.9%. Total IGF-1 was measured in plasma by ELISA (R&D Systems) with an intra-assay CV of 3.5%–4.3% and an interassay CV of 7.5%–8.3%.

**Statistics.** To calculate how the observation of no $^{15}$N-thymidine–labeled nuclei (Figure 2) affects the probability of different yearly adipogenesis rates, we assumed homogeneity of the subjects and pooled the data, assuming that each measurement of an adipocyte nucleus was independent. The probability is expressed as $P (R_{avg yearly birth rate} \mid no \ 15^N \ nucleus) = [1 - R \times (no. \ days \ labeling / 365)]^{total \ no. \ nucleus}$, where $P$ represents probability, $R$ represents the hypothetical yearly birth rate, and $no \ 15^N \ nucleus$ represents the observed absence of $^{15}$N-thymidine-labeled adipocyte nuclei.

**Hormonal analyses.** Total adiponectin was measured in plasma by ELISA (R&D Systems) with an intra-assay coefficient of variation (CV) of 2.5%–4.7% and an interassay CV of 5.8%–6.9%. Total leptin was measured in plasma by ELISA (R&D Systems) with an intra-assay CV of 3.0%–3.3% and an interassay CV of 5.8%–6.9%. Total IGF-1 was measured in plasma by ELISA (R&D Systems) with an intra-assay CV of 3.5%–4.3% and an interassay CV of 7.5%–8.3%.
Technological advance

Statistical analyses were performed using JMP Pro 11.0 (SAS Institute Inc.) and Prism 6 (Graphpad). A 2-sided P value of less than 0.05 was considered significant. Means and SEM are reported unless the data were not normally distributed, in which case a median and interquartile range are reported. Univariate relationships were calculated using Pearson correlation coefficients or, if the data were not normally distributed, Spearman’s coefficients. Least-squares linear regression was used to control for variables in a multivariable analysis. As adipogenesis calculated by nuclear H-labeling was nonnormally distributed even after attempts at normalization, we performed a least-squares linear regression using the nonnormally distributed data (reported in Table 3) and confirmed these results by (a) performing a rank-based analysis by ranking the data from 1 to 9 and using these ranked data in the least-squares linear regression model and (b) removing the largest value for the outcome variable, which normalized the data, and repeating the least-squares linear regression. Importantly, the results reported in Table 3 remained consistent with these two confirmatory analyses.

Study approval
The study was approved by the Partners Institutional Review Board, run by the Partners Healthcare Human Research Committee, Boston, Massachusetts, USA. Written informed consent was obtained from all subjects before their participation in the study.

Author contributions
EDR, RTL, CPL, and MLS conceptualized the study; CG, CPL, and MLS developed methodology; PKF, HL, and MLS performed formal analysis; CG, SK, ML, JPZ, JM, and MLS performed experiments; HFSC, FH, and DL provided resources; PKF and MLS wrote the manuscript; MLS facilitated visualization; RTL and MLS supervised the study; MLS was the project administrator; and EDR, RTL, CPL, and MLS acquired funding.

Acknowledgments
We thank CAMECA and F. Hillion for providing usage of a NanoSIMS instrument, which was used for the development of analytical strategies utilized in this study. We thank T. Perlstein for assistance with the human protocols. This work was funded by resources from the clinical research center and by a pilot grant (to EDR, RTL, CPL, and MLS) both from the Harvard Catalyst (NCATS/NIH UL1 TR001102 to EDR, RTL, CPL, and MLS), the Harvard Stem Cell Institute (to MLS), and Brigham and Women’s Hospital Funds (to MLS).

Address correspondence to: Matthew L. Steinhauser, 77 Avenue Louis Pasteur, New Research Building, Room 458, Boston, Massachusetts 02115, USA. Phone: 617.525.4716; E-mail: msteinhauser@partners.org.


